Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faceptor vs Herceptin in HER2+ Metastatic Breast Cancer
NCT05301530Phase 1Completed
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- May 2019
- Primary completion
- Aug 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of trastuzumab in HER2-positive metastatic breast cancer (2 arms), sponsored by Nanogen Pharmaceutical Biotechnology JSC. Primary endpoints: Serum Peak Concentration and Area Under the Curve from 0 to t. Started May 2019; status: completed.
02
Drugs
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT05301530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05301530.